Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

SIMPLE SUMMARY: Tyrosine kinase inhibitor treatment has greatly improved the prognosis for many chronic myeloid leukaemia patients; however, disease progression is usually fatal for patients and remains a significant clinical challenge today. Using the UK SPIRIT 2 (STI571 Prospective International R...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Richard E., Basabrain, Ammar A., Austin, Gemma M., Holcroft, Alison K., Loaiza, Sandra, Apperley, Jane F., Law, Christopher, Scott, Laura, Parry, Alexandra D., Bonnett, Laura, Lucas, Claire M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124525/
https://www.ncbi.nlm.nih.gov/pubmed/33947031
http://dx.doi.org/10.3390/cancers13092155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124525/
https://www.ncbi.nlm.nih.gov/pubmed/33947031
http://dx.doi.org/10.3390/cancers13092155

Ejemplares similares